Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 56 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsActive, not recruitingNCT05544552Phase 1/2
• Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsStatus unknownNCT05537987Phase 1
• HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingNCT05535933Phase 2/3
• ABSK091 Food Effect Study in Healthy SubjectsCompletedNCT05533788Phase 1
• Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.CompletedNCT05529667Phase 1/2
• Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult SubjectsCompletedNCT05528120Phase 1
• Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 InfectionActive, not recruitingNCT05527418Phase 2
• A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)Active, not recruitingNCT05526755Phase 2
• Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)TerminatedNCT05524857Phase 1
• Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)CompletedNCT05524311Phase 2
• Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver MetastasisStatus unknownNCT05524155Phase 2
• A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisCompletedNCT05523765Phase 2
• Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
• A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaActive, not recruitingNCT05520567Phase 1/2
• Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT05517330Phase 2
• Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCCompletedNCT05516589Phase 2
• Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC TrialWithdrawnNCT05514912Phase 2
• A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant CancerActive, not recruitingNCT05514496Phase 1
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With RemibrutinibActive, not recruitingNCT05513001Phase 3
• Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
• Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated CytopeniasWithdrawnNCT05509582Phase 2
• Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2
• Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2
• Single Dose Glumetinib in Healthy Chinese Male SubjectsCompletedNCT05507294Phase 1
• Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver DiseaseCompletedNCT05506488Phase 1/2
• Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2
• Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLStatus unknownNCT05498259Phase 2
• A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
• Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedNCT05494580Phase 1/2
• A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.CompletedNCT05493995Phase 2
• Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
• First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruitingNCT05489237Phase 1
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Phase 1/2
• Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic DermatitisCompletedNCT05487963Phase 1/2
• Drug-drug Interactions Between AZD4205 and Itraconazole/CarbamazepineCompletedNCT05486949Phase 1
• A Study of Diet Influence of AL8326 in Chinese Healthy Adult SubjectsStatus unknownNCT05486598Phase 1
• Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand EczemaCompletedNCT05486117Phase 1
• Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2
• Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05485350Phase 2
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerWithdrawnNCT05481775Phase 2
• Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.TerminatedNCT05481645Phase 2
• Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT05481476Phase 2
• Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy SubjectsCompletedNCT05478772Phase 1
• Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesTerminatedNCT05477615Phase 2
• Single Dose Study To Study The Absorption, Metabolism And Excretion Of FamitinibStatus unknownNCT05473468Phase 1
• Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia AreataActive, not recruitingNCT05470413Phase 3
• Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543CompletedNCT05468749Phase 1
• Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543CompletedNCT05467722Phase 1
• Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy SubjectsCompletedNCT05467709Phase 1
• Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy VolunteersCompletedNCT05467696Phase 1
• A Study of Olverembatinib in the Treatment of Ph+ ALLStatus unknownNCT05466175Phase 2
• Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionActive, not recruitingNCT05466149Phase 2
• Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)CompletedNCT05465343Phase 2
• Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve PatientsActive, not recruitingNCT05463224Phase 2
• Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsStatus unknownNCT05460481Phase 2
• Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCStatus unknownNCT05458726Phase 2
• Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2
• Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With AnlotinibStatus unknownNCT05453383Phase 2
• Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract CancerActive, not recruitingNCT05451290Phase 2
• Masitinib for the Treatment of Severe Mast Cell Activation SyndromeStatus unknownNCT05449444Phase 2
• Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal CancerStatus unknownNCT05447715Phase 2
• A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in MyelofibrosisStatus unknownNCT05447260Phase 4
• Baricitinib for Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownNCT05446831Phase 2
• Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast CancerCompletedNCT05444998Phase 2
• TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05441956Phase 1
• Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisSuspendedNCT05441488Phase 3
• Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
• Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsActive, not recruitingNCT05438420Phase 1/2
• A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisCompletedNCT05437263Phase 3
• Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationTerminatedNCT05435846Phase 1
• Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
• TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsActive, not recruitingNCT05434312Phase 1
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
• Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCCActive, not recruitingNCT05433116Phase 2
• A Study of LP-168 in Healthy VolunteersCompletedNCT05432713Phase 1
• Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisCompletedNCT05432596Phase 2
• Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsCompletedNCT05431634Phase 1
• Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsWithdrawnNCT05431582Phase 1
• A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
• Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCStatus unknownNCT05430386Phase 1
• Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
• Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038Status unknownNCT05429294Phase 2
• Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive, not recruitingNCT05425940Phase 3
• Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT05420220Phase 2
• Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair SystemWithdrawnNCT05419817Phase 2
• Drug-drug Interactions Between DZD9008 and Itraconazole/CarbamazepineCompletedNCT05418582Phase 1
• Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CMLTerminatedNCT05413915Phase 3
• Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans SyndromeStatus unknownNCT05413356Phase 2
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver MetastasisStatus unknownNCT05406466Phase 2
• Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line TherapyStatus unknownNCT05406206Phase 2
• Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
• Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory MyopathiesStatus unknownNCT05400889Phase 2
• R-MTX-zanbrutinib in Secondary CNS LymphomaStatus unknownNCT05398224Phase 2
• Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingNCT05396859Phase 1
• A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction CancerStatus unknownNCT05395780Phase 2
• Regorafenib in Patients With Refractory Primary Bone TumorsCompletedNCT05395741Phase 1/2
• Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2
• Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
• A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy VolunteersCompletedNCT05392127Phase 1
• Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular CarcinomaStatus unknownNCT05391867Not applicable

← Tyrosine Kinase Inhibitors overview